Subscribe
shutterstock_685347493_katherine_welles
Katherine Welles / Shutterstock.com
5 February 2020AmericasSarah Morgan

BMS partners with drug accelerator to launch biotech

Bristol-Myers Squibb (BMS) and BioMotiv, a drug development accelerator, have launched Anteros Pharmaceuticals, a biotech focused on developing a new class of drugs for fibrotic and other inflammatory diseases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

More on this story

Americas
Bristol-Myers Squibb to acquire Celgene in $74bn deal
3 January 2019   American pharmaceutical company Bristol-Myers Squibb has announced it is purchasing drug manufacturer Celgene in a $74 billion deal.
Americas
BMS pays $1.85bn for immuno-oncology programme
15 February 2018   Bristol-Myers Squibb has agreed to pay $1.85 billion for an immuno-oncology programme.
Americas
BMS to acquire Forbius in oncology expansion
27 August 2020   Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool